Trials / Completed
CompletedNCT04242199
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors
A Phase 1 Study Exploring the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Select Advanced Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 182 (actual)
- Sponsor
- Incyte Corporation · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics, pharmacodynamics, and early clinical activity of INCB099280 in participants with select solid tumors
Conditions
- Advanced Solid Tumor
- MSI-H/dMMR Tumors
- Cutaneous Squamous Cell Carcinoma
- Urothelial Carcinoma
- Cervical Cancer
- HepatoCellular Carcinoma
- Esophageal Squamous Cell Carcinoma
- Merkel Cell Carcinoma
- Small-cell Lung Cancer
- Mesothelioma
- PD-L1 Amplified Tumor (9p24.1)
- Nasopharyngeal Carcinoma
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | INCB099280 | INCB099280 administered orally in 25 mg or 100 mg tablets once daily or twice daily on each day of each 28-day cycle |
Timeline
- Start date
- 2020-09-04
- Primary completion
- 2024-08-29
- Completion
- 2024-11-21
- First posted
- 2020-01-27
- Last updated
- 2025-07-14
Locations
21 sites across 5 countries: United States, Australia, Belgium, France, Japan
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04242199. Inclusion in this directory is not an endorsement.